muciniphila is capable of attenuating metabolic syndrome and damage to the intestinal mucosa by inducing an anti-inflammatory response and controlling intestinal homeostasis
Primary sources from the demand side include healthcare professionals from hospitals, nursing care facilities, long-term health centers, and ambulatory surgical centers
Its oral small-molecule design improves accessibility and patient compliance compared to injectables
Semaglutide (Wegovy) and tirzepatide (Zepbound) have demonstrated significant average weight loss14.9% and 20.9% of body weight at approximately one year, respectively
non-exclusive, field of use, territory), the transferability of the license in the transaction (assignment provisions, change-of-control clauses), the financial terms (upfront fees, milestones, royalties, and royalty stacking provisions), the maintenance obligations (diligence requirements that could cause termination if the acquirer deprioritizes the program), and the duration and termination provisions